Amneal Pharmaceuticals, Inc. AMRX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Business | ||||||
| Affordable Medicines | $423.24M+2.1% | $436.65M-0.6% | $460.74M+7.8% | $433.43M+1.4% | $414.71M+6.0% | |
| AvKARE | $166.02M-3.7% | $210.74M+23.7% | $198.53M+24.5% | $163.04M-4.3% | $172.42M+6.0% | |
| Specialty | $133.27M+23.1% | —— | $125.24M+8.3% | $128.04M+23.1% | $108.3M+2.9% | |
| Net revenue by Product | ||||||
| Auto-Injector | $41.91M-13.0% | $39.1M+3.1% | $78.94M+11.7% | $66.59M+14.3% | $48.16M+13.0% | |
| Biosimilar | $22.3M-21.9% | $29.43M-23.7% | $17.01M-44.6% | $25.25M-14.4% | $28.54M+6.9% | |
| Central nervous system | $83.38M+23.3% | $104.75M+36.8% | $77.63M+5.8% | $83.43M+30.5% | $67.61M+2.0% | |
| Distribution | $89.15M-15.0% | $107.68M+1.1% | $96.22M-5.3% | $99.66M-14.2% | $104.9M-4.4% | |
| Government label | $59.95M+19.6% | $86.79M+85.2% | $87.76M+109% | $45.42M+25.4% | $50.14M+43.5% | |
| Hormonal / allergy | $35.93M+5.1% | $47.63M+28.7% | $37.69M+16.7% | $35.42M+11.5% | $34.2M+16.4% | |
| Injectable | $49.94M+43.5% | $37.44M-21.9% | $54.37M+25.9% | $34.65M-11.3% | $34.79M-1.2% | |
| Institutional | $9.82M-10.8% | $8.38M-21.9% | $5.85M-37.7% | $10.13M-13.9% | $11.01M+1.4% | |
| International | $5.32M+331% | $2.7M+109% | $6.29M+39.5% | $1.9M+32.9% | $1.23M-28.3% | |
| Oral liquid | $12.09M-48.6% | $14.98M-39.7% | $16.42M-27.2% | $17.88M-25.8% | $23.55M-26.2% | |
| Oral solid | $171.1M-4.4% | $188.71M+3.1% | $180.46M+11.9% | $178.26M+1.3% | $178.95M+5.7% | |
| Other dosage forms | $46.61M-17.4% | $68.15M+15.6% | $59.66M+17.8% | $68.19M+38.3% | $56.42M+30.4% | |
| Other therapeutic classes | $13.95M+115% | $14.55M+101% | $9.92M+25.5% | $8.7M+4.1% | $6.49M+27.1% | |
| Subtotal dosage forms | $417.92M+1.1% | $433.95M-0.9% | $454.45M+7.5% | $431.52M+1.3% | $413.47M+6.1% | |
| Subtotal therapeutic classes | $133.27M+23.1% | $166.93M+38.1% | $125.24M+10.3% | $127.54M+22.6% | $108.3M+7.5% | |
| Transdermal | $73.96M+71.8% | $56.14M+19.9% | $47.6M+8.4% | $40.71M-18.1% | $43.06M+6.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amneal Pharmaceuticals, Inc. break its business down?
- Amneal Pharmaceuticals, Inc. (AMRX) reports net revenue by business across 3 parts — Affordable Medicines, AvKARE and Specialty. Each is extracted from the segment footnotes and tracked over time.
- Where does Amneal Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amneal Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
